PDCD1 and head and neck squamous cell carcinoma: PD-1/PD-L1 ICIs have been shown to provide therapeutic advantages for recurrent or metastatic HNSCC cases, as compared to standard chemotherapies [55,56,57]; the combination of cetuximab with PD-1 ICIs provides promising clinical data [58].